Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the effect of the recombinant zoster vaccine on the risk of developing new dementia diagnoses among adults aged 76 years or older living in Finland. This phase IV pragmatic trial aims to assess whether receiving this vaccine influences the incidence of dementia, including Alzheimers disease, over a long follow-up period. Participants will be randomly assigned to receive either the vaccine or a placebo. Participants in the vaccine group receive two doses of the recombinant zoster vaccine the first dose on Day 1 and the second dose between 2 and 6 months later, following the approved dosing schedule. Those in the placebo group receive two doses of placebo injections on the same schedule. The study is randomized, placebo-controlled, and observer-blind to compare outcomes between these two groups. During the study, participants will be followed for up to 10 years after their first dose to monitor for new dementia diagnoses, death, or loss to follow-up. Researchers will use health register data to assess outcomes including new diagnoses of dementia and Alzheimers disease. Safety monitoring includes exclusion of severely immunocompromised individuals and those living in nursing facilities. The total participation duration allows long-term observation of vaccine effects on dementia risk.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and tolerability of a new multivalent pneumococcal vaccine called PG4 in healthy infants. The study compares this new vaccine to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC to see how well they protect against infections like pneumonia, meningitis, and ear infections caused by Streptococcus pneumoniae. The trial is a Phase 3, randomized, double-blinded study involving about 2400 infants around 2 months old. Participants will be randomly assigned to receive either the new PG4 vaccine or the 20vPnC vaccine. Both vaccines are given as injections into the left thigh muscle at 2, 4, 6, and between 12 to 15 months of age. The study lasts about 16 to 19 months, during which infants will have six clinic visits and one phone call to monitor their health and any side effects. During these visits, parents or legal guardians will report any local reactions, systemic events, or other adverse effects experienced by the infant after each vaccine dose. Researchers will track events occurring within seven days after each dose, as well as serious adverse events up to six months following the last dose. The goal is to understand the safety profile of the new vaccine compared to the existing one over the course of the study period.
Actively Recruiting
Researchers are comparing the safety and effectiveness of laparoscopic cholecystectomy versus a wait-and-see approach in elderly patients who have had successful endoscopic removal of common bile duct stones. The study aims to determine if waiting without immediate surgery is not worse than having the gallbladder removed laparoscopically. The main goal is to observe death, major postoperative complications, or recurrent biliary disease within one year after randomization. Four hundred participants aged 75 or older with cleared bile duct stones are randomly assigned to one of two groups. One group receives laparoscopic cholecystectomy within two weeks after stone removal, while the other group is managed without surgery initially but can have cholecystectomy later if needed. An interim safety analysis is planned after 100 participants to ensure no significant differences arise between groups. The trial may end early if strong evidence shows a difference in outcomes. Participants are followed for up to one year after randomization to track the composite outcome of death, major complications, or biliary events. Researchers also monitor quality of life, survival, healthcare costs, and pain related to biliary issues at various time points. The study includes assessments at 30, 180, and 365 days, with additional monitoring of hospitalizations and complications extending to two years in some measures.
Actively Recruiting
Researchers are evaluating the performance, usability, and safety of a new physiological monitoring technology designed to collect electrocardiogram ECG and respiration-related data. This study includes participants from all age groups, including neonates, children, adults, and elderly subjects, to support device development and clinical evaluation under various clinical conditions. Participants will be monitored using the investigational heart rate and impedance respiration monitor cable while hospitalized. Data collection will focus on ECG and respiration measurements during their hospital stay, with a maximum data collection period of up to 24 hours after enrollment. The study aims to improve measurement technologies, assist in product development, and provide clinical evidence for safety, performance, and regulatory compliance. During the study, participants will remain in the hospital unit where the monitoring device is used, with continuous data collection of physiological signals. Researchers will assess the devices performance, usability, and safety based on the collected data. The total participation time is up to 24 hours after enrollment, with no additional long-term follow-up reported.
Actively Recruiting
Healthy Volunteer
Researchers are investigating the complex causes and cellular makeup of hip osteoarthritis OA using advanced single-cell and spatial omics technologies. The study aims to identify different cell types in synovial tissues and blood samples from OA patients, compare these to non-arthritic tissues, explore inflammatory responses, uncover key molecular pathways, and differentiate OA subtypes. A sub-study also compares tissue and blood from patients with rheumatoid arthritis RA to better understand differences in disease mechanisms. The study involves three groups adults with hip OA undergoing elective total hip arthroplasty, adults with hip RA undergoing elective total hip arthroplasty, and non-arthritic adults undergoing trauma-based emergency total hip arthroplasty as controls. Researchers collect tissue and blood samples for detailed analysis using single-cell RNA sequencing and spatial omics to map the transcriptome and proteome while preserving tissue structure. Participants will undergo hip joint replacement surgery and provide samples for molecular analysis. The study timeline includes characterizing cell populations from early 2025 to late 2026, mapping cellular landscapes through 2026, identifying molecular pathways through 2027, and comparing RA and OA disease mechanisms through 2028. Researchers also study potential blood biomarkers and OA subtypes. The total duration spans several years with ongoing assessments and molecular mapping.
Actively Recruiting
Researchers are evaluating the use of intravenous IV contrast-enhanced computed tomography CT compared to native CT without contrast in adults with acute abdominal pain who have impaired kidney function. This study addresses concerns about the risk of post-contrast acute kidney injury PC-AKI in patients with reduced renal function, aiming to provide clearer evidence through a randomized controlled trial. The trial focuses on patients with an estimated glomerular filtration rate eGFR between 15 and 45 mlmin1.73 m2 who require emergency abdominal or body CT scans. Participants are randomly assigned to one of two groups one receiving abdominal or body CT with IV contrast, and the other receiving abdominal or body CT without IV contrast native CT. This open-label trial is conducted at multiple centers, comparing the effects and outcomes of these two imaging methods in patients with impaired kidney function. The study is designed to determine if the use of IV contrast affects mortality or the need for renal replacement therapy. During the study, researchers will monitor participants for outcomes including all-cause mortality and renal replacement therapy within 90 days after the CT scan. Additional evaluations include measuring acute kidney injury within 72 hours, any organ failure within 48 hours, hospital-free days within 90 days, and the time from CT to definitive treatment during the hospital stay. Participants will be followed closely after their CT scan to assess these outcomes and ensure safety throughout the study period.
Actively Recruiting
This research aims to identify factors linked to no improvement in gastrointestinal quality of life after elective laparoscopic cholecystectomy for gallstones. The study focuses on patients who have symptomatic gallstones and undergo this surgery, with the goal of understanding outcomes related to abdominal symptoms and quality of life. Participants are observed without any additional intervention. The study monitors patients following their scheduled laparoscopic cholecystectomy, tracking their recovery and quality of life over time to gather data on gastrointestinal health. During the study, participants will complete questionnaires to assess their gastrointestinal quality of life using the GIQLI score at one year after surgery. Researchers will analyze these results to understand the impact of the surgery on abdominal symptoms and overall well-being. The study is observational and involves regular follow-up assessments over the course of the study period.
Actively Recruiting
This clinical trial investigates adult patients suspected of having appendicitis. It compares protocol-based selective imaging methods to routine imaging with ultrasound andor computed tomography CT. The study aims to determine if using clinical scoring to guide imaging or observation affects clinical outcomes, specifically the rates of negative appendectomies and complicated appendicitis. Participants are randomly assigned to one of three groups one group receives routine imaging starting with ultrasound and followed by CT if needed the second group receives selective imaging guided by the Adult Appendicitis Score AAS, with urgent surgery scheduled for high scores the third group undergoes selective observation based on the Appendicitis Severity Score ASS combined with selective imaging based on the AAS. Imaging and treatment decisions are made according to these scoring protocols. During the study, participants undergo abdominal imaging and clinical scoring assessments. Researchers monitor outcomes such as negative appendectomies and complicated appendicitis within 30 days after randomization. Secondary measures include confirmed appendicitis, CT scan use, adverse events up to one year, quality of life assessments, and costs during the first 30 days. The study follows participants for appendicitis outcomes up to two years.
Actively Recruiting
Researchers are conducting a randomized trial to compare two pain management methods during laparoscopic cholecystectomy LCC surgery, which treats conditions like gallstones, gallbladder inflammation, and gallbladder cancer. The study evaluates whether a combination of a laparoscopic ropivacaine transversus abdominis plane TAP block plus local trocar site infiltration called STALL is more effective than local wound infiltration alone for pain control. This trial aims to provide clearer evidence on the benefits of adding the TAP block to local anesthesia. Participants are assigned to one of several groups based on their surgery type daycare, inpatient, or emergency surgery. Each group either receives local trocar site ropivacaine infiltration alone or combined with the laparoscopically guided TAP block. Both procedures involve using ropivacaine to numb the surgical area, delivered during the laparoscopic procedure. The trial compares these methods to see which better controls pain after surgery. During the study, researchers monitor participants opioid use in the recovery area lasting about 1 to 4 hours as the primary outcome. Secondary measures include pain scores recorded for two days after surgery and total opioid use during hospital stays for inpatient or emergency cases. The study is double-blinded and randomized, ensuring unbiased comparison. Participants will be followed until the end of their recovery, and the trial completes by late 2027.
Actively Recruiting
Researchers are investigating long-term outcomes in survivors of out-of-hospital cardiac arrest, focusing on how different targets for sedation, temperature, and blood pressure management affect brain protection and recovery. This study is part of a larger international, multi-center randomized trial called STEPCARE. The study also explores the impact of caregiving on those caring for cardiac arrest survivors. Participants in the STEPCARE trial are randomly assigned to various combinations of sedation levels deep or minimal, temperature management using a feedback-controlled device or fever control without a device, and blood pressure targets high MAP above 85 mmHg or low MAP above 65 mmHg. These interventions are applied during the initial treatment period. The extended follow-up substudy enrolls survivors from selected sites who consent, following them and their nominated caregivers at 6 and 12 months after cardiac arrest. During the follow-up, researchers assess cognitive function of survivors using the Montreal Cognitive Assessment MoCA and measure caregiver burden with the Zarit Burden Interview ZBI at 6 months. The study includes questionnaires and evaluations to understand recovery and caregiving challenges. Participants are monitored over a total of 12 months, with data collected at both 6 and 12 months to evaluate long-term effects of the initial treatments and caregiving experiences.
1-10 of 12
1